Product Information
METHYLPHENIDATE ER(LA) 30 MG CP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.9037 per EA under NDC 00093534701. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 13, 2012.
Strength
30 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093534701
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA079031FDA Approved
7/13/2012
On Market Since
7/16/2012
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE ER(LA) 30 MG CP has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 55.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.9037 per EA |
|---|---|
| All-time high | $5.0876 (Sep 14, 2016) |
| All-time low | $1.0799 (May 19, 2021) |
| 52-week high | $2.9073 |
| 52-week low | $1.9037 |
| Median price | $3.2395 |
| Average price | $3.1117 |
| Largest weekly change | +71.5% (Aug 23, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE ER(LA) 30 MG CP?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE ER(LA) 30 MG CP, manufactured by Teva Pharmaceuticals USA Inc., is $1.9037 per EA (NDC 00093534701), effective Sep 30, 2026.
How has the price of METHYLPHENIDATE ER(LA) 30 MG CP changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE ER(LA) 30 MG CP has declined 55.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE ER(LA) 30 MG CP?
Since Nov 28, 2013, the NADAC for METHYLPHENIDATE ER(LA) 30 MG CP has ranged from a low of $1.0799 (May 19, 2021) to a high of $5.0876 (Sep 14, 2016), with a median of $3.2395 per EA.
Are there cheaper alternatives to METHYLPHENIDATE ER(LA) 30 MG CP?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE ER(CD) 30 MG CP, is $1.7946 per EA — about 6% below METHYLPHENIDATE ER(LA) 30 MG CP.
Who manufactures METHYLPHENIDATE ER(LA) 30 MG CP?
METHYLPHENIDATE ER(LA) 30 MG CP (NDC 00093534701) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.